{
    "Clinical Trial ID": "NCT02203565",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Supportive Care (Dakin's Solution, Radiation Therapy)",
        "  Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.",
        "  Dakin's solution: Applied topically",
        "  radiation therapy: Undergo radiation therapy",
        "  questionnaire administration: Ancillary studies",
        "  laboratory biomarker analysis: Optional correlative studies"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Women with breast cancer who plan to undergo radiation therapy to the breast or chest wall",
        "  Ability to understand and the willingness to sign a written informed consent document",
        "Exclusion Criteria:",
        "  Women with scleroderma or discoid lupus",
        "  Women with inflammatory breast cancer as evidenced by clinical assessment",
        "  Women with breast cancer involving the skin",
        "  Women who have undergone prior radiotherapy to the chest wall and/or breast"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percent of Women Who Develop Grade 3 or 4 Radiation Dermatitis (as Defined by the Stanford Radiation Dermatitis Scoring System) During a Course of Radiation Therapy",
        "  Stanford Radiation Dermatitis Scoring System:",
        "  Grade Clinical finding",
        "  0 No skin change",
        "  1 Faint, barely detectable erythema 2 Follicular rash, hyperpigmentation, evolving erythema 3 Dry desquamation, brisk erythema 4 Moist desquamation 5 Bleeding, ulceration, and/or infection",
        "  Time frame: Baseline to up to 6 weeks after completion of therapy",
        "Results 1: ",
        "  Arm/Group Title: Supportive Care (Dakin's Solution, Radiation Therapy)",
        "  Arm/Group Description: Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.",
        "  Dakin's solution: Applied topically",
        "  radiation therapy: Undergo radiation therapy",
        "  questionnaire administration: Ancillary studies",
        "  laboratory biomarker analysis: Optional correlative studies",
        "  Overall Number of Participants Analyzed: 14",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  6  42.9%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 3/20 (15.00%)",
        "  Dermatitis radiation 3/20 (15.00%)"
    ]
}